Method of detecting endometrial cancer comprising measuring levels of fibrocystin-L
View Patent ↗Nucleic acids encoding fibrocystin-L polypeptides and fibrocystin-L polypeptides are provided. Antibodies against the polypeptides, vectors and host cells containing the nucleic acids, methods for using the nucleic acids and polypeptides, and compositions and articles of manufacture also are provided.
1. A method for determining whether a subject has endometrial cancer, comprising:
(a) using an antibody having specific binding affinity for a fibrocystin-L polypeptide comprising the amino acid sequence of SEQ ID NO:3 to measure the level of fibrocystin-L polypeptide in an endometrial sample from the subject, and
(b) determining that the subject has endometrial cancer if the level of fibrocystin-L polypeptide in the endometrial sample is increased relative to the level in a corresponding control sample, or determining that the subject does not have endometrial cancer if the level of fibrocystin-L polypeptide in the endometrial sample is not increased relative to the level in the corresponding control sample.
2. The method of claim 1 , wherein step (a) comprises using immunohistochemistry, western blotting, or ELISA.
3. A method for determining whether an endometrial tissue sample from a subject contains cancer cells, comprising:
(a) measuring the level of fibrocystin-L in the endometrial tissue sample by contacting the sample with an antibody having specific binding affinity for a fibrocystin-L polypeptide comprising the amino acid sequence of SEQ ID NO:3, and
(b) determining that the sample contains cancer cells if the level of fibrocystin-L in the sample is increased relative to a control level, or determining that the sample does not contain cancer cells if the level of fibrocystin-L in the sample is not increased relative to the control level.